ALDX vs. CDT, QURE, OVID, ACIU, TSVT, ACRV, ME, IMMP, FHTX, and GTHX
Should you be buying Aldeyra Therapeutics stock or one of its competitors? The main competitors of Aldeyra Therapeutics include Conduit Pharmaceuticals (CDT), uniQure (QURE), Ovid Therapeutics (OVID), AC Immune (ACIU), 2seventy bio (TSVT), Acrivon Therapeutics (ACRV), 23andMe (ME), Immutep (IMMP), Foghorn Therapeutics (FHTX), and G1 Therapeutics (GTHX). These companies are all part of the "pharmaceutical preparations" industry.
Conduit Pharmaceuticals (NASDAQ:CDT) and Aldeyra Therapeutics (NASDAQ:ALDX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.
Aldeyra Therapeutics has a consensus target price of $9.33, suggesting a potential upside of 137.49%. Given Conduit Pharmaceuticals' higher probable upside, analysts clearly believe Aldeyra Therapeutics is more favorable than Conduit Pharmaceuticals.
3.3% of Conduit Pharmaceuticals shares are held by institutional investors. Comparatively, 59.7% of Aldeyra Therapeutics shares are held by institutional investors. 23.5% of Conduit Pharmaceuticals shares are held by company insiders. Comparatively, 7.3% of Aldeyra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Aldeyra Therapeutics' return on equity of 0.00% beat Conduit Pharmaceuticals' return on equity.
In the previous week, Aldeyra Therapeutics had 2 more articles in the media than Conduit Pharmaceuticals. MarketBeat recorded 3 mentions for Aldeyra Therapeutics and 1 mentions for Conduit Pharmaceuticals. Aldeyra Therapeutics' average media sentiment score of 1.00 beat Conduit Pharmaceuticals' score of 0.34 indicating that Conduit Pharmaceuticals is being referred to more favorably in the media.
Aldeyra Therapeutics received 478 more outperform votes than Conduit Pharmaceuticals when rated by MarketBeat users.
Conduit Pharmaceuticals has a beta of 2.47, suggesting that its stock price is 147% more volatile than the S&P 500. Comparatively, Aldeyra Therapeutics has a beta of 1.51, suggesting that its stock price is 51% more volatile than the S&P 500.
Summary
Conduit Pharmaceuticals beats Aldeyra Therapeutics on 6 of the 11 factors compared between the two stocks.
Get Aldeyra Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for ALDX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ALDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aldeyra Therapeutics Competitors List
Related Companies and Tools
